Rineterkib
| Catalog Number | Pack Size | List Price* | Quantity | |
|---|---|---|---|---|
| HY-114491-1MG | 1 mg | 164,00 | Add | |
| HY-114491-5MG | 5 mg | 330,00 | Add | |
| HY-114491-10MMO | 10mM/1mL | 416,00 | Add | |
| HY-114491-10MG | 10 mg | 584,00 | Add | |
| HY-114491-25MG | 25 mg | 1'217,00 | Add | |
| HY-114491-50MG | 50 mg | 2'103,00 | Add | |
| HY-114491-100MG | 100 mg | 3'750,00 | Add |
* CHF, excl. 8.1% VAT and shipping costs
Product Description
Best price guarantee – we offer you the lowest price in Switzerland. Please contact us for a quote if needed.
Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF[1][2].
| Category | Biochemicals |
| Supplier | MedChem Express |
| Regulatory Status | RUO |
| Research Field | Cancer, MAPK/ERK Pathway,Stem Cell/Wnt |
| Format | Solubility: DMSO : 200 mg/mL (ultrasonic) |
| Grade | Clinical information: Phase 2 |
| Purity | 99.83% |
| Molecular Formula | C26H27BrF3N5O2 |
| Molecular Weight | 578.42 |
| CAS-Number | 1715025-32-3 |
| Storage Conditions | 4°C (Powder, sealed storage, away from moisture and light) |
| Tech. Data Sheet | View datasheet |
| Link To Supplier | http://www.medchemexpress.com |
| Shipping Details | Room Temperature |
| Material Safety Data Sheet | Download PDF |
